The Relative Strength (RS) Rating for BeOne Medicines ADR jumped into a new percentile Tuesday, with a rise from 79 to 83.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of other stocks on the major indexes.
Over 100 years of market history reveals that the top-performing stocks tend to have an 80 or better RS Rating as they begin their biggest climbs.
BeOne Medicines ADR is working on a consolidation with a 287.88 entry. See if it can break out in heavy trade.
The company showed 0% earnings growth in the latest quarterly report, while sales growth came in at 49%.
BeOne Medicines ADR earns the No. 18 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Anbio Biotechnology are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
